Cannabis Law Report

MARCH 26, 2022

Construction has begun on a medical cannabis manufacturing facility which will create more than 100 jobs. Jazz Pharmaceuticals is investing £75m in a plant based at Kent Science Park (KSP) in Sittingbourne, Kent.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

FEBRUARY 23, 2022

(TSX: LABS) (OTCQX: MEDIF ) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. These projects will all require pharmaceutical approved API if commercialized. Management Commentary.

Pharmaceutical 52

Pharmaceutical Research and Development Extraction Cannabinoids 52

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Business 52

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Project CBD

JULY 28, 2023

Scialdone is a founding member of the Cannabis Chemistry Subdivision of the American Chemical Society from which he received the 2018 CANN-CHAS Heidolph Award for Excellence in Cannabis Chemistry. These are not present in cannabis and are only formed in the chemical conversion, whose impact on human health is unknown.

THC 212

THC Cannabinoids Hemp Research and Development 212

Cannabis Law Report

DECEMBER 10, 2022

BusinessCann reports Oxford Cannabinoid Technologies (OCT) has seen its share price jump by more than 20% this week after announcing that its CEO Dr John Lucas would be stepping down. The pharmaceutical company announced on Monday, December 5 that Dr Lucas would leave the company by the end of the year, staying on until then […].

Cannabinoids 52

Cannabinoids Pharmaceutical Compliance Compliance 52

Cannabis Law Report

DECEMBER 3, 2020

3, 2020 /PRNewswire/ — Pure Jamaican Limited , provider of pharmaceutical cannabinoids, genetics and consumer packaged goods products in large volumes for … Read More. MIAMI , Dec.

Pharmaceutical 64

Pharmaceutical Legislation Packaging Cannabinoids 64

Cannabis Law Report

AUGUST 10, 2021

This authorisation for TSC, represents the fourth approved indication of a cannabis-based medicine in the UK for GW and underlines GW’s commitment to the UK and regulatory approved cannabis-based medicines. “We The safety profile observed was consistent with findings from previous studies, with no new safety risks identified.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

APRIL 22, 2021

Patent protects Supera-CBD, a preclinical cannabidiol derivative that targets cannabinoid receptor type 2 for the treatment of neuroinflammatory and neurodegenerative… Read More.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment CBD 98

Cannabis Law Report

SEPTEMBER 8, 2021

The mission of the United Cannabis Business Association is to establish a comprehensive, statewide cannabinoid policy. Responsible policy prioritizes public health and safety and promotes the viability of both California’s legal cannabis industry and the legal hemp industry. .

Cannabinoids 95

Cannabinoids Policy Advocacy Hemp 95

Cannabis Law Report

OCTOBER 5, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Kind Meds (Cannabis Education Blog)

JANUARY 27, 2022

Since the popularization of CBD in recent years, it’s more common to see cannabis recognized as a true medical treatment. However, CBD and the psychoactive THC aren’t the only compounds found in the cannabis plant. Lately, the cannabinoid CBN (or cannabinol) has been rising in popularity. What Is CBN? How Is CBN Created?

Cannabinoids 52

Cannabinoids Treatment Extraction THC 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Veriheal

AUGUST 12, 2021

million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). In addition to this, the survey results featured responses from 138 patients who did not use any type of cannabis product.

Epilepsy 58

Epilepsy Pharmaceutical Patients Sleep 58

Cannabis Law Report

JANUARY 20, 2022

Proactive Research analyst Ed Stacey presents his analysis on Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company specialising in drug development from cannabinoids (compounds derived from cannabis).

Cannabinoids 52

Cannabinoids Research and Development Pharmaceutical Medicine 52

Cannabis Law Report

SEPTEMBER 17, 2021

Patent 16/424,351, a Cannabinoid Composition and Method of Sublingual, Buccal, and Oral Mucosa Delivery. This patent focuses on a formulation that includes a cannabinoid extract that is pharmaceutically effective by systemic delivery to the recipient’s oral mucosal lining. is a women-led cannabinoid health science company.

Cannabinoids 52

Cannabinoids Pharmaceutical Digestion Terpenes 52

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”). Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

The Fresh Toast

SEPTEMBER 22, 2023

The Research About Fibromyalgia And Cannabis Even though pharmaceutical drugs and OTC pain-relievers are typically used to help manage fibromyalgia, cannabinoids like CBD and THC are being considered more now than ever before. If you had to guess, how many people in the United States do you think live with fibromyalgia?

Pharmaceutical 73

Pharmaceutical Cannabinoids THC Cannabis 73

Cannabis Law Report

AUGUST 12, 2022

. – August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL.

Extraction 52

Extraction Pharmaceutical Patients THC 52

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. Pre-Close Trading Update; US OTC QB Market Application. & & Notice of 2021 Final Results. . Details of a presentation to investors via the InvestorMeet Platform will be announced shortly. Since the year-end, the £2.6

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

AUGUST 27, 2021

based cannabis tech company Nextleaf Solutions Ltd. (CSE: cannabis patents to date. cannabis patents to date. Nextleaf Solutions’s technologies are focused on transforming cannabis or hemp biomass to a standardized cannabinoid oil as efficiently as possible. Health Canada Standard Processor and Vancouver, B.C.-based

Extraction 98

Extraction Cannabinoids Research and Development Oil 98

SpeedWeed

AUGUST 8, 2021

It’s the first cannabis-derived pharmaceutical to be legalized in many countries around the world, including the UK, Spain, United States, Canada, and New Zealand. . “It’s not just street cannabis put into a bottle,” GW Pharmaceutical CEO Justin Gover once told the Guardian. View original article.

Cannabinoids 64

Cannabinoids Pharmaceutical DEA Medicine 64

Cannabis Life Network

MAY 5, 2019

The acquisition brings together Canopy Growth‘s medical business with Europe’s largest cannabinoid-based pharmaceuticals company. C3 is a leading manufacturer and distributor of dronabinol, a registered pharmaceutical drug in Germany, Austria, Switzerland, and Denmark.

Cannabinoids 44

Cannabinoids Pharmaceutical Patients Business 44

Cannabis Law Report

NOVEMBER 13, 2021

A cardiologist with no public comments on cannabinoid therapies, Dr. Robert Califf, has been nominated to take over as commissioner of the U.S. Califf has said nothing publicly about cannabinoids such as CBD. Hemp Today reports. Food and Drug Administration. More at [link].

Cannabinoids 52

Cannabinoids Therapy Pharmaceutical Hemp 52

Cannabis Law Report

JUNE 1, 2022

(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Europe and Latin America, announces that it has entered into an agreement to acquire Pharmadrug GmbH from its parent PharmaDrug Inc. CSE:PHRX) (OTC:LMLLF). This will have a direct positive impact on our revenues and higher gross margins.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

PrestoDoctor

DECEMBER 12, 2023

The Use of Cannabis Among Seniors More and more seniors are turning to cannabis as an alternative to traditional medications. As the stigma surrounding cannabis use decreases and more research shows the potential benefits, older adults are exploring this natural remedy for various ailments.

Medicine 98

Medicine Chronic Pain Consumption Pharmaceutical 98

Cannabis Law Report

JULY 28, 2021

On 1 June 2021, the Group announced an agreement with Voisin Consulting SARL (“VC”), a life sciences consultancy comprising over 200 professionals in the UK, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addictions.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

The Cannigma

NOVEMBER 16, 2022

Can cannabis reduce acid reflux and heartburn? 6 medicinal plants that pharmaceuticals can't replace. At this point, there simply isn’t much research on cannabis use to combat acid reflux and GERD. Cannabis and acid reflux: the research. How might cannabis be able to help with acid reflux? Related Stories.

Digestion 119

Digestion Cannabinoids Pharmaceutical THC 119

United Patients Group

FEBRUARY 7, 2023

Benefits of Cannabis for Inflammation and Pain Introduction Inflammation and pain are two of the most common health issues that many people face. Cannabis has been used as medicine for thousands of years, and there are many different ways this plant can help with inflammation and pain relief by interacting with our bodies in different ways.

Cannabinoids 114

Cannabinoids Chronic Pain Terpenes THC 114

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 12, 2021

IRISYS, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that it was awarded… Read More.

Treatment 59

Treatment Cannabinoids Pharmaceutical Law 59

Veriheal

JANUARY 26, 2023

According to recent research, cannabis could offer unique benefits as part of an approach to managing bipolar disorder. In this article, we’ll explore how the potential advantages of cannabis might help stabilize symptoms associated with bipolar disorder. Most commonly, pharmaceutical medication is prescribed to regulate moods.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

SpeedWeed

JULY 29, 2021

Why do you consume cannabis? In addition to THC and CBD, hemp and cannabis contain dozens of other cannabinoids that can aid everything from appetite suppression and weight loss to fighting insomnia or inflammation. Cannabis and weight loss don’t usually roll off the tongue together. THCV for Energy and Weight Loss.

Sleep 52

Sleep Cannabinoids Oil THC 52

Leafwell

JANUARY 15, 2021

As common wisdom knows, marijuana is reputed to be the world’s safest drug, whether those proactive cannabinoids are purchased and ingested through the pharmaceutical or artisanal marketplaces. We believe knowledge is power and Leafwell seeks to educate not only patients but medical professionals as well.

Pharmaceutical 117

Pharmaceutical Education Cannabinoids Patients 117

Leafwell

JANUARY 15, 2021

As common wisdom knows, marijuana is reputed to be the world’s safest drug, whether those proactive cannabinoids are purchased and ingested through the pharmaceutical or artisanal marketplaces. We believe knowledge is power and Leafwell seeks to educate not only patients but medical professionals as well.

Pharmaceutical 117

Pharmaceutical Education Cannabinoids Patients 117